Mocumbi A, Humbert M, Saxena A, Jing Z-C, Sliwa K, Thienemann F, et al. Pulmonary hypertension. Nat Rev Dis Prim. 2024;10(1):1.

Article  PubMed  Google Scholar 

Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12S):S5–12.

Article  Google Scholar 

Ewert R, Schäper C, Halank M, Gläser S, Opitz CF. Inhalative iloprost–pharmacology and clinical application. Expert Opin Pharmacother. 2009;10(13):2195–207.

Article  CAS  PubMed  Google Scholar 

Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: a therapeutic review. Drug Des Dev Ther. 2012:19–28.

Khan S, Randhawa S, Patail H, Spira Y, Frishman WH, Aronow WS, et al. Pharmacological update and emerging treatments of pulmonary hypertension. Cardiol Rev. 2024:10.1097.

Swisher JW, Weaver E. The evolving management and treatment options for patients with pulmonary hypertension: current evidence and challenges. Vasc Health Risk Manag. 2023;19:103–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhand R. Intelligent nebulizers in the age of the Internet: The I-neb adaptive aerosol delivery (AAD) system. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA; 2010. pp. iii–v.

Hardaker LE, Hatley RH. In vitro characterization of the I-neb adaptive aerosol delivery (AAD) system. J Aerosol Med Pulmon Drug Deliv. 2010;23(S1):S-11–S-20.

Gessler T. lloprost delivered via the BREELIBTM nebulizer: a review of the clinical evidence for efficacy and safety. Ther Adv Respir Dis. 2019;13:1753466619835497.

Article  PubMed  PubMed Central  Google Scholar 

Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir Soc. 2011;37:1308.

Article  CAS  Google Scholar 

El-Kersh K, Jalil BA. Pulmonary hypertension inhaled therapies: an updated review. Am J Med Sci. 2023;366:3–15.

Article  PubMed  Google Scholar 

Spikes LA, Bajwa AA, Burger CD, Desai SV, Eggert MS, El-Kersh KA, et al. BREEZE: open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension. Pulmon Circ. 2022;12(2): e12063.

Article  CAS  Google Scholar 

Rinderknecht CH, Ning M, Wu C, Wilson MS, Gampe C. Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities. Expert Opin Drug Discov. 2024;19:1–14.

Article  Google Scholar 

Darquenne C, Corcoran TE, Lavorini F, Sorano A, Usmani OS. The effects of airway disease on the deposition of inhaled drugs. Expert Opin Drug Deli. 2024 (just-accepted).

Taylor G. The pharmacokinetics of inhaled drugs. J Aerosol Med Pulm Drug Deliv. 2023;36(5):281–8.

Article  CAS  PubMed  Google Scholar 

Matera MG, Rinaldi B, Page C, Rogliani P, Cazzola M. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Metab Toxicol. 2018;14(10):1101–11.

Article  CAS  PubMed  Google Scholar 

Stockmann C, Roberts JK, Yellepeddi VK, Sherwin CM. Clinical pharmacokinetics of inhaled antimicrobials. Clin Pharmacokinet. 2015;54:473–92.

Article  CAS  PubMed  Google Scholar 

Lu D, Lee SL, Lionberger RA, Choi S, Adams W, Caramenico HN, et al. International guidelines for bioequivalence of locally acting orally inhaled drug products: similarities and differences. AAPS J. 2015;17:546–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gessler T. Inhalation of repurposed drugs to treat pulmonary hypertension. Adv Drug Deliv Rev. 2018;133:34–44.

Article  CAS  PubMed  Google Scholar 

Enlo-Scott Z, Bäckström E, Mudway I, Forbes B. Drug metabolism in the lungs: opportunities for optimising inhaled medicines. Expert Opin Drug Metab Toxicol. 2021;17(5):611–25.

Article  CAS  PubMed  Google Scholar 

Soulele K, Macheras P, Silvestro L, Savu SR, Karalis V. Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers. Eur J Pharm Sci. 2015;80:33–42.

Article  CAS  PubMed  Google Scholar 

Tang C, Ou-Yang C-X, Chen W-J, Zou C, Huang J, Cui C, et al. Prediction of pharmacokinetic parameters of inhaled indacaterol formulation in healthy volunteers using physiologically-based pharmacokinetic (PBPK) model. Eur J Pharm Sci. 2022;168:106055.

Article  CAS  PubMed  Google Scholar 

Borghardt JM, Weber B, Staab A, Kunz C, Kloft C. Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation. Br J Clin Pharmacol. 2016;82(3):739–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi C, Ignjatović J, Liu T, Han M, Cun D, Đuriš J, et al. In vitro-in vivo-in silico approach in the development of inhaled drug products: nanocrystal-based formulations with budesonide as a model drug. Asian J Pharm Sci. 2021;16(3):350–62.

PubMed  PubMed Central  Google Scholar 

Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv. 2008;21(1):1–12.

Article  CAS  PubMed  Google Scholar 

Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12S):S13–24.

Article  Google Scholar 

Buckley MS, Feldman JP. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults. Pharmacotherapy. 2010;30(7):728–40.

Article  CAS  PubMed  Google Scholar 

Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008;31(4):891–901.

Article  CAS  PubMed  Google Scholar 

Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492.

Article  PubMed  PubMed Central  Google Scholar 

Haché M, Denault A, Bélisle S, Robitaille D, Couture P, Sheridan P, et al. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. J Thorac Cardiovasc Surg. 2003;125(3):642–9.

Article  PubMed  Google Scholar 

Nicolas LB, Krause A, Gutierrez MM, Dingemanse J. Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects. Br J Clin Pharmacol. 2012;74(6):978–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehta PP, Dhapte-Pawar VS. Repurposing drug molecules for new pulmonary therapeutic interventions. Drug Deliv Transl Res. 2021;11:1829–48.

Article  PubMed  Google Scholar 

Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev. 2009;18(111):29–34.

Article  CAS  PubMed  Google Scholar 

Skuballa W, Radüchel B, Vorbrüggen H, editors. Chemistry of stable prostacyclin analogues: synthesis of iloprost. Prostacyclin and its stable analogue Iloprost. Berlin: Springer; 1987.

Gessler T, Ghofrani H-A, Held M, Klose H, Leuchte H, Olschewski H, et al. The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. Pulmon Circ. 2017;7(2):505–13.

Article  CAS  Google Scholar 

Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest. 2003;124(4):1294–304.

Article  CAS  PubMed  Google Scholar 

Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol. 1986;30:61–8.

Article  CAS  PubMed  Google Scholar 

Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800–4.